In vitro antifungal susceptibility patterns of planktonic and sessile Candida kefyr clinical isolates

被引:13
|
作者
Nagy, Fruzsina [1 ]
Bozo, Aliz [1 ]
Toth, Zoltan [1 ]
Daroczi, Lajos [2 ]
Majoros, Laszlo [1 ]
Kovacs, Renato [1 ,3 ]
机构
[1] Univ Debrecen, Fac Med, Dept Med Microbiol, Nagyerdei Krt 98, H-4032 Debrecen, Hungary
[2] Univ Debrecen, Fac Sci & Technol, Dept Solid State Phys, Debrecen, Hungary
[3] Univ Debrecen, Fac Pharm, Debrecen, Hungary
关键词
biofilm; echinocandins; caspofungin; amphotericin B; scanning electron microscopy; INTENSIVE-CARE-UNIT; AMPHOTERICIN-B; HEMATOLOGIC MALIGNANCIES; BIOFILMS; CASPOFUNGIN; MICAFUNGIN; VITRO; FLUCONAZOLE; ALBICANS; KEFYR;
D O I
10.1093/mmy/myx062
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The activity of fluconazole, amphotericin B, caspofungin and micafungin was determined using XTT-based fungal damage assays against planktonic cells, early and mature biofilms of Candida kefyr. Median MICs of planktonic cells were 0.25 mg/l, 0.25 mg/l, 0.5 mg/l, and 0.06 mg/l for fluconazole, amphotericin B, caspofungin, and micafungin, respectively. Fluconazole showed at least 50% fungal damage at >= 4 mg/l (51.5% +/- 6.63% to 78.38% +/- 1.44%) and at >= 128 mg/l (57.88% +/- 9.2% to 67.25% +/- 9.59%), while amphotericin B produced an even higher anti-biofilm effect at >= 0.5 mg/l (64.63% +/- 6.79% to 79.5% +/- 5.9%) and at >= 0.12 mg/l (77.63% +/- 8.43% to 92.75% +/- 1.89%) against early and mature biofilms, respectively. In case of micafungin, 50% fungal damage was observed at >= 0.06 mg/l (66.88% +/- 10.16% to 98.63% +/- 1.24%) and >= 0.25 mg/l (74.13% +/- 10.77% to 99.38% +/- 0.38%) for early and mature biofilms, respectively. Caspofungin-exposed cells showed an unexpected susceptibility pattern, that is, planktonic cells showed significantly decreased susceptibility at concentrations ranging from 0.015 mg/l to 1 mg/l compared to biofilms (P < .05-.01). The damage in planktonic cells and biofilms was comparable at higher concentrations. For planktonic cells and biofilms, 50% fungal damage was observed first at 0.5 mg/l (59.75% +/- 3.16%) and at 0.06 mg/l (70.25% +/- 10.95%), respectively. This unexpected pattern was confirmed using scanning electron microscopy. The unusual susceptibility pattern observed at lower caspofungin concentrations may explain the poorer outcome of caspofungin-treated C. kefyr infections documented in certain patient populations. As this phenomenon was markedly less apparent in case of micafungin, these data suggest that micafungin may be a more reliable option than caspofungin for the treatment of C. kefyr infections.
引用
收藏
页码:493 / 500
页数:8
相关论文
共 50 条
  • [31] Susceptibility in vitro of clinical Candida albicans isolates to the selected azoles
    Pawlicki, Bartlomiej
    Biernasiuk, Anna
    Jonczyk, Monika
    Malm, Anna
    [J]. CURRENT ISSUES IN PHARMACY AND MEDICAL SCIENCES, 2021, 34 (02) : 77 - 80
  • [32] Identification and in vitro antifungal susceptibility testing of 200 clinical isolates of Candida spp. responsible for fingernail infections
    Valda Teixeira Figueiredo
    Daniel de Assis Santos
    Maria Aparecida Resende
    Júnia Soares Hamdan
    [J]. Mycopathologia, 2007, 164 : 27 - 33
  • [33] Identification and in vitro antifungal susceptibility testing of 200 clinical isolates of Candida spp. responsible for fingernail infections
    Figueiredo, Valda Teixeira
    Santos, Daniel de Assis
    Resende, Maria Aparecida
    Hamdan, Junia Soares
    [J]. MYCOPATHOLOGIA, 2007, 164 (01) : 27 - 33
  • [34] In vitro antifungal susceptibility to six antifungal agents of 229 Candida isolates from patients with diabetes mellitus
    Manfredi, M
    McCullough, MJ
    Polonelli, L
    Conti, S
    Al-Karaawi, ZM
    Vescovi, P
    Porter, SR
    [J]. ORAL MICROBIOLOGY AND IMMUNOLOGY, 2006, 21 (03): : 177 - 182
  • [35] SUSCEPTIBILITY OF CLINICAL ISOLATES OF CANDIDA SPP TO TERCONAZOLE AND OTHER AZOLE ANTIFUNGAL AGENTS
    PFALLER, MA
    GERARDEN, T
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1989, 12 (06) : 467 - 471
  • [36] Comparative study of antifungal susceptibility testing methods for clinical Candida albicans isolates
    Tan, Xue Ting
    Shuhairi, Nurliyana binti Mohd
    Tap, Ratna Mohd
    Amran, Fairuz
    [J]. INDIAN JOURNAL OF MEDICAL MICROBIOLOGY, 2024, 50
  • [37] Variations in DNA subtype and antifungal susceptibility among clinical isolates of Candida tropicalis
    Zhang, J
    Hollis, RJ
    Pfaller, MA
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1997, 27 (03) : 63 - 67
  • [38] Antifungal susceptibility of Candida clinical isolates in Canada:: a ten-year review
    Fuller, J.
    Sand, C.
    Rennie, R.
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2007, 29 : S563 - S563
  • [39] Epidemiology and antifungal susceptibility patterns of Candida isolates from Greek women with vulvovaginal candidiasis
    Maraki, Sofia
    Mavromanolaki, Viktoria Eirini
    Stafylaki, Dimitra
    Nioti, Eleni
    Hamilos, George
    Kasimati, Anna
    [J]. MYCOSES, 2019, 62 (08) : 692 - 697
  • [40] IDENTIFICATION OF CANDIDA SPECIES FROM CLINICAL SAMPLES AND THEIR ANTIFUNGAL SUSCEPTIBILITY PATTERNS
    Bhaskar, U. A.
    Rai, Yashavanth
    Ronald, R.
    [J]. JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS, 2015, 4 (75): : 12998 - 13004